Evidence map›Paper›PMID 38696611›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Transmural Flow Upregulates PD-L1 Expression in Microvascular Networks.

Zhengpeng Wan, Shun Zhang, Amy X Zhong, Liling Xu, Mark F Coughlin, Georgios Pavlou, Sarah E Shelton, Huu Tuan Nguyen, Satomi Hirose, Seunggyu Kim and 4 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Transmural Flow Upregulates PD-L1 Expression in Microvascular Networks.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhengpeng WanDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Shun ZhangDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Amy X ZhongDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Liling XuRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Mark F CoughlinDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Georgios PavlouDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Sarah E SheltonDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Huu Tuan NguyenDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Satomi HiroseDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Seunggyu KimDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Marie A FloryanDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
F Stephen HodiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Roger D KammDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID 0000-0002-7232-304X

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint BlockadeU01CA214381 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BARBIE, DAVID A, KAMM, ROGER D · 2017 to 2021
$3.5M
Imaging Cancer Angiogenesis with Acoustic Angiography UltrasoundK00CA212227 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHELTON, SARAH ELIZABETH · 2018 to 2021
$392k
Koch Institute Support P30-CA14051National Cancer Institute Tissue Engineering ConsortiumNCI NIH HHS K00 CA212227NCI NIH HHS K00CA212227NCI NIH HHS P30 CA014051NCI NIH HHS U01 CA214381Swiss National Science Foundation SNSF-P400PB_186779
6 · The paper itself

Abstract

Endothelial programmed death-ligand 1 (PD-L1) expression is higher in tumors than in normal tissues. Also, tumoral vasculatures tend to be leakier than normal vessels leading to a higher trans-endothelial or transmural fluid flow. However, it is not clear whether such elevated transmural flow can control endothelial PD-L1 expression. Here, a new microfluidic device is developed to investigate the relationship between transmural flow and PD-L1 expression in microvascular networks (MVNs). After treating the MVNs with transmural flow for 24 h, the expression of PD-L1 in endothelial cells is upregulated. Additionally, CD8 T cell activation by phytohemagglutinin (PHA) is suppressed when cultured in the MVNs pre-conditioned with transmural flow. Moreover, transmural flow is able to further increase PD-L1 expression in the vessels formed in the tumor microenvironment. Finally, by utilizing blocking antibodies and knock-out assays, it is found that transmural flow-driven PD-L1 upregulation is controlled by integrin α

Indexed as

B7-H1 AntigenMicrovesselsUp-RegulationAnimalsEndothelial CellsHumansMiceTumor MicroenvironmentB7-H1 AntigenCD274 protein, humanintegrin αVβ3microfluidicmicrovasculaturePD‐L1transmural flowtumor microenvironment

Identifiers

PMID38696611
PMCPMC11234398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.